Alert detail

LCD L37295: MolDX: EndoPredict® Breast Cancer Gene Expression Test — Noridian

Policy ID: LCD-L37295Specialty: OncologyAdded: 6/5/2026Effective: January 22, 2026lcd
Routine

What changed

New billing guidelines for EndoPredict® test coming in 2026.

Who’s affected: Oncology billing teams · Effective: January 22, 2026

Affected codes

Codes81522

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

This change affects 3 billing codes.

Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.

Audit documentation

Building an audit file?

The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Oncology audit pack — $349One-time purchase · not a subscription

Not ready to subscribe?

Get the free weekly reimbursement brief for Oncology— the week’s changes and deadlines, delivered to your inbox. No account required.

LCD L37295: MolDX: EndoPredict® Breast Cancer Gene Expression Test — Noridian